Compare EML & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EML | TTRX |
|---|---|---|
| Founded | 1858 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.2M | 116.0M |
| IPO Year | 1995 | N/A |
| Metric | EML | TTRX |
|---|---|---|
| Price | $20.51 | $3.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 15.9K | 14.4K |
| Earning Date | 06-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.10% | N/A |
| EPS Growth | ★ 185.40 | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $248,970,345.00 | N/A |
| Revenue This Year | $19.05 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.61 | $2.57 |
| 52 Week High | $26.78 | $5.98 |
| Indicator | EML | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.31 | 50.93 |
| Support Level | $17.96 | $3.55 |
| Resistance Level | $20.93 | $4.01 |
| Average True Range (ATR) | 0.66 | 0.21 |
| MACD | 0.26 | 0.05 |
| Stochastic Oscillator | 77.30 | 51.47 |
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.